TruScreen Group Ltd. ( ($NZ:TRU) ) just unveiled an announcement.
TruScreen Group Ltd., a dual-listed medical device maker on the NZX and ASX, has developed the TruScreen Ultra, an AI-enabled cervical cancer screening device that delivers real-time analysis without the need for traditional tissue sampling or specialised laboratory infrastructure. The device holds regulatory approvals and guideline endorsements across a wide range of markets, including China, Vietnam, Russia, Mexico, and several other countries, and supports growing global adoption via a manufacturing base in China and an expanding installed footprint.
The company has announced a change of auditors, with Hall Chadwick NZ Limited resigning and audit partner Vinay Sheoran, operating through Hall Chadwick (NSW) Limited, becoming the new registered audit provider. TruScreen said the move, which shifts the audit function from New Zealand to New South Wales, is intended to streamline audit processes and better align with the fact that its operations are now predominantly based in New South Wales, signalling an operational centre of gravity increasingly rooted in Australia.
The change in audit location may improve oversight efficiency and coordination between the company’s core operations and its external auditors, which can be material for financial reporting quality and regulatory compliance. For investors and other stakeholders, the announcement underlines TruScreen’s evolving operational footprint and suggests a further consolidation of its governance and compliance functions around its main operating base in New South Wales.
More about TruScreen Group Ltd.
TruScreen Group Ltd. is a medical device company specialising in AI-enabled cervical cancer screening technology that analyses cervical tissue in real time using optical and electrical measurements. Its flagship product, TruScreen Ultra, is approved or registered in multiple major markets including Australia, the U.K., China, Russia, Mexico, Vietnam, and others, with over 200 devices installed and more than 200,000 examinations performed in financial year 2024.
The company’s technology is incorporated into national and specialist cervical cancer screening guidelines in China, Vietnam, and Russia, and is supported by a manufacturing facility in China for locally marketed devices. TruScreen targets both public and private healthcare sectors globally through distributors in 29 countries, positioning itself as a key player in cervical cancer prevention with the vision of a world without cervical cancer.
Average Trading Volume: 512,231
Technical Sentiment Signal: Sell
Current Market Cap: N$12.7M
See more insights into TRU stock on TipRanks’ Stock Analysis page.
